The US Food and Drug Administration has set a goal date under the Biosimilar User Fee Act of 27 December this year for Mylan and Biocon’s proposed biosimilar to Genentech’s Avastin (bevacizumab), following the FDA’s acceptance of Mylan’s biologics license application filing.
“The BLA seeks approval of bevacizumab for first-line and second-line treatment of patients with metastatic colorectal cancer in combination with fluorouracil-based chemotherapy; first-line use for patients with non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?